Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Achilles Therapeutics plc (NASDAQ: ACHL) will have its CEO Dr. Iraj Ali and EVP Dr. Ed Samuel participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023, at 11:30 am ET (4:30 pm UK). The event will focus on the company's development of AI-powered precision T cell therapies aimed at treating solid tumors. Achilles is conducting two Phase I/IIa trials: the CHIRON trial for advanced non-small cell lung cancer and the THETIS trial for recurrent or metastatic melanoma. Investors can access a live and archived webcast of the presentation on the company's website under the Events & Presentations section.
- None.
- None.
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, and Dr. Ed Samuel, EVP, Technical Operations, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023, at 11:30am ET / 4:30pm UK.
A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Forward Looking Statements
This press release contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Investors:
Lee M. Stern
VP, IR & External Communications
ir@achillestx.com
Media:
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com
FAQ
What is the upcoming event for Achilles Therapeutics on April 24, 2023?
Who will represent Achilles Therapeutics at the Chardan Summit?
What therapies is Achilles Therapeutics developing?
What are the current clinical trials being conducted by Achilles Therapeutics?
Where can I watch the presentation from Achilles Therapeutics?
